載入中
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
前收盤價
US$0.6445
−US$0.0478 · -6.90%
盤中時間採用ET。市場資料可能有所延遲。
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
日內區間
目前US$0.6445
52週區間
目前US$0.6445
盤中時間採用ET。市場資料可能有所延遲。
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
日內區間
目前US$0.6445
52週區間
目前US$0.6445
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 135.1萬 USD | 135.1萬 USD |
| 銷貨成本 | 8.7萬 USD | — | 30.2萬 USD | — | — |
| 毛利 | −8.7萬 USD | — | −30.2萬 USD | 135.1萬 USD | 135.1萬 USD |
| 研究與開發 | 438.8萬 USD | 264.4萬 USD | 727.2萬 USD | 2558.2萬 USD | 3688.8萬 USD |
| 銷售、一般及管理費用 | 455.7萬 USD | 611萬 USD | 750.7萬 USD | 1300.8萬 USD | 3070.3萬 USD |
| 營業費用 | 885.8萬 USD | 875.4萬 USD | 1477.9萬 USD | 3859萬 USD | 6759.1萬 USD |
| 利息收入 | 7.8萬 USD | 5.9萬 USD | 42.1萬 USD | 19.5萬 USD | 9.8萬 USD |
| 利息支出 | — | — | — | 1.7萬 USD | 8.7萬 USD |
| 折舊和攤銷 | 8.7萬 USD | 28.5萬 USD | 30.2萬 USD | 23.2萬 USD | 6.1萬 USD |
| 營業利益 | −894.5萬 USD | −875.4萬 USD | −1508.1萬 USD | −3723.9萬 USD | −6624萬 USD |
| 淨利 | −799.2萬 USD | −1112.3萬 USD | −2102.6萬 USD | −3327.9萬 USD | −6417.9萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
